2023
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
de Mesquita Y, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao E, Carvalho P, da Silva C, Cardoso R, Moura F, Rafalskiy V. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. International Journal Of Obesity 2023, 47: 883-892. PMID: 37460681, DOI: 10.1038/s41366-023-01337-x.Peer-Reviewed Original ResearchConceptsMean differenceRandomized controlled trialsOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsControlled trialsMeta-analysisCo-primary endpointsMethodsWe searched PubMedType 2 diabetesAgonist tirzepatideRisk of biasReview Manager 5.4.1Receptor agonistsReduced BMITherapeutic optionsWaist circumferenceAdverse eventsTirzepatideGastrointestinal symptomsPooled analysisGLP-1PlaceboWeight management
2022
Tirzepatide for diabetes: on track to SURPASS current therapy
Moura F, Scirica B, Ruff C. Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine 2022, 28: 450-451. PMID: 35260841, DOI: 10.1038/s41591-022-01733-2.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesDiabetes MellitusGastric Inhibitory PolypeptideHumansHypoglycemic Agents
2019
Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
Cintra R, Moura F, Carvalho L, Barreto J, Tambascia M, Pecoits-Filho R, Sposito A. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista Da Associação Médica Brasileira 2019, 65: 70-86. PMID: 30758423, DOI: 10.1590/1806-9282.65.1.70.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsRisk of hypoglycemiaAntidiabetic therapySodium-glucose co-transporter 2High risk of hypoglycemiaIncreased risk of hypoglycemiaPrevalence of type 2 diabetes mellitusType 2 diabetes mellitusRenal proximal convoluted tubulesChronic kidney diseaseCo-morbid diseasesSystolic blood pressurePost hoc studyProximal convoluted tubulesReduced insulin sensitivitySGLT2i therapyMedian ageSodium-glucoseSodium reabsorptionOlder individualsClinical trialsIncreased riskKidney diseaseBlood pressureConvoluted tubules